Welcome to Bristol Myers Squibb California

Bristol Myers Squibb’s robust and growing presence in California is transforming the way cancer and other difficult-to-treat diseases are approached. 

Scientists and researchers with diverse backgrounds and expertise in San Diego, Redwood City, Brisbane and San Francisco collaborate across teams, functions and sites to follow their own scientific curiosity, enabling fast, flexible science that ultimately increases the efficiency and success of drugs in the clinic. These efforts, at a time when the pace of technological advancements and creation of new biomedical knowledge is accelerating, are laying the foundation for investigational molecules that may one day have a significant therapeutic impact.

Meet our team

Learn about our leaders who are making a difference in California.

Kristen Hege and her work at Bristol Myers Squibb >

Kristen Hege, M.D., is responsible for overseeing early clinical development programs for a diverse range of treatment modalities such as CAR T cells, T-cell engagers, monoclonal antibodies and small molecules.

Debbie Law and her work at Bristol Myers Squibb >

Debbie Law (DPhil) is head of Bristol Myers Squibb’s Tumor Microenvironment (TME) Thematic Research Center, leading a team of researchers who explore the complexities of tumors, with a specific focus on the environment the tumor creates.

Mark Rolfe and his work at Bristol Myers Squibb >

Mark Rolfe, Ph.D., leads an early drug discovery team focused on targeted protein degradation – removing disease-causing proteins from cells by leveraging the body’s natural system of maintaining balanced protein levels.

Chetana Rao and her work at Bristol Myers Squibb >

Chetana Rao, Ph.D., leads site and strategy operations at Bristol Myers Squibb’s Redwood City and San Francisco sites, as well as diversity and inclusion initiatives for the company in the Bay area. 

Miranda Broz and her work at Bristol Myers Squibb >

Miranda Broz, Ph.D., serves on a team responsible for exploring parts of the tumor microenvironment (TME) to better uncover how a tumor functions, with the hope of eventually turning these findings into novel treatment options that will benefit patients with difficult-to-treat cancers. 

Join us as we transform patient lives through science 

Every day, each of us work to improve outcomes of patients fighting serious diseases. Together we’re building a better future for each other and the patients who need us the most. 

Driving innovation forward in California

Learn about our broad scope of scientific innovation in California.

Confronting the complexities of cancer >

Bristol Myers Squibb is driven to understand human biology and the complexities of cancer in order to advance the next generation of cancer therapies.

Looking to the future of cell therapy >

Bristol Myers Squibb is pursuing a multitude of diverse approaches in cell therapy to attack disease from new perspectives. 

Protein homeostasis 101: a Q&A with Mark Rolfe >

Hear from Mark Rolfe, Ph.D., as he describes protein homeostasis and protein degradation, and how the company is leveraging this novel research to make a difference for patients.

Building on today’s science to research medicines of tomorrow >

As a scientific research community, our work is never done for cancer patients. Building upon established science allows researchers to pursue new approaches, test new hypotheses and – ultimately – uncover new answers to emerging and enduring questions that may address unmet needs for patients. 

Community impact

Learn about how we are making a difference in communities across California

People and business resource groups >

People and Business Resource Groups (PBRGs) represent one key strategy we use to support the business objectives, career advancement and development needs of our employees.

California regional fact sheet >

Learn more about our impact in California.

Improving science education >

Science and technology are at the core of everything we do. We're always eager to open young minds to the exciting possibilities of both. 

University of California San Francisco partnership >

University of California San Francisco will create an in-person and virtual-based patient navigation program to enhance the quality of cancer care for English, Chinese, and Vietnamese patients newly diagnosed with colorectal, liver, or lung cancer in the Greater San Francisco Bay Area.

University of California Irvine Chao Family Comprehensive Cancer Center (CFCCC) partnership >

The CFCCC will build a formal collaborative network as a hub/spoke model between community organizations, CalOptima primary and specialty care providers, and UCI’s specialists to provide more efficient and effective cancer care for low income MediCal Vietnamese, Korean, and Chinese patients in Orange County, California. 

University of California Davis and HALO Clinic partnership >

University of California Davis, in a collaborative partnership with the Health and Life Organization, will prospectively identify and follow Asian American patients across the cancer continuum to improve cancer prevention and control behaviors to create a New Patient Referral service between a federally qualified healthcare center lookalike and National Cancer Institute Comprehensive Cancer Center.

Additional resources

Learn more about our scientific approaches and innovation.

Protein degradation resources >

Learn about the science behind protein degradation and ongoing research that harnesses the power of this natural process.

Tumor microenvironment resources >

Exploring the tumor microenvironment (TME) to better understand how cancer and the immune system coexist is a core component of Bristol Myers Squibb’s research and early development strategy.

Cell therapy resources >

Novel cell-based therapies that use a person’s own cells are unlocking new potential in the fight against some of the most difficult-to-treat cancers.